Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BLISSGVS.NS
Strong BuyPremium GrowerBliss GVS Pharma Limited · Healthcare · India · $810M · Avg Vol: $3M/d
87
StockRankGet insider-trade alerts
Q
77
V
18
M
89
P/E (TTM)
54.8x
ROE
10.8%
D/E
0.0x
Dividend %
0.2%
COMPANY DESCRIPTION
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 7.5B | 7.7B | 8.0B | 9.2B | 7.2% | 10.1B |
| EPS (INR) | 6.83 | 7.23 | 8.02 | 12.23 | 21.4% | 12.64 |
| Shares | 104.2M | 104.7M | 105.4M | 105.8M | +1.6% | 106.3M |
| Debt | 1.0B | 998.4M | 881.0M | 217.5M | -40.2% | 217.5M |
| Equity | 8.8B | 9.7B | 10.5B | 11.9B | 10.5% | — |
| Op CF | 343.1M | 1.0B | 1.1B | 1.4B | 59.3% | 1.4B |
| Inv CF | -77.5M | -831.9M | -755.9M | -382.8M | — | — |
| Fin CF | -249.4M | -208.9M | -302.0M | -892.1M | — | — |
Loading 1Y...
PRICE (1Y)+51.9%
SMA 50SMA 200
Close
$7.29
RSI (14)
73.4
52W High
$7.63
From 52W High
1.0%
SCORE BREAKDOWN
Quality
77
ROIC
16.6%86.4
ROE
10.8%72.7
GP/Assets
35.8%72.1
Op. Margin
23.3%86.8
FCF/Assets
5.5%71.9
Piotroski
783.9
Int. Cover
29.4x74.6
D/E Ratio
0.02x80.9
Current Ratio
4.02x65.5
Value
18
P/E (TTM)
54.8x19.9
EV/EBITDA
39.1x15.8
P/FCF
94.1x17.1
P/B
6.1x22.2
P/S
7.3x32.0
Div Yield
0.2%5.2
Momentum
89
52W High %
95%94.4
RS 6M
215%99.5
SMA 50/200
1.65x99.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
16%52.0
FUNDAMENTALS
Market Cap
$810M
P/E (Forward)
—
Gross Margin
53.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLISSGVS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BLISSGVS.NS | Bliss GVS Pharma Limited(you) | $810M | 87 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $696M | 89 | Strong Buy |
| MOREPENLAB.NS | Morepen Laboratories Limited | $677M | 85 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $653M | 89 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| PGHL.NS | Procter & Gamble Health Limited | $981M | 92 | Strong Buy |
| INNOVACAP.NS | Innova Captab Limited | $707M | 79 | Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 93 | Strong Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| AKUMS.NS | Akums Drugs and Pharmaceuticals Limited | $1.2B | 95 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%